New Expert Consensus Highlights Lifestyle Choices in Treating Major Depressive Disorder The American College of Lifestyle Medicine has released a consensus affirming the efficacy of lifestyle interventions in combating major depressive disorder, offering important guidance for mental health care.

New Expert Consensus Highlights Lifestyle Choices in Treating Major Depressive Disorder #United_States #St._Louis #Lifestyle_Interventions #Major_Depressive_Disorder #American_College_of_Lifestyle_Medicine

New Clinical Findings Enhance CAPLYTA®'s Promise for Major Depressive Disorder Remission Recent data reveals that CAPLYTA® (lumateperone) significantly increases remission rates in adults with major depressive disorder, offering hope for better treatment outcomes.

New Clinical Findings Enhance CAPLYTA®'s Promise for Major Depressive Disorder Remission #United_States #Titusville #Major_Depressive_Disorder #CAPLYTA® #lumateperone

Gilgamesh Pharma's Blixeprodil Shows Promise in Treating Major Depression: Phase 2a Results Revealed Gilgamesh Pharma has released promising topline results for their NMDA receptor antagonist Blixeprodil, showing significant antidepressant effects in patients with Major Depressive Disorder.

Gilgamesh Pharma's Blixeprodil Shows Promise in Treating Major Depression: Phase 2a Results Revealed #United_States #New_York #Major_Depressive_Disorder #Gilgamesh_Pharma #Blixeprodil

Biohaven Reports Phase 2 Trial Results for BHV-7000 in Treating Major Depression Biohaven Ltd. shares results from a Phase 2 study of BHV-7000 for major depressive disorder, highlighting safety and subgroup trends.

Biohaven Reports Phase 2 Trial Results for BHV-7000 in Treating Major Depression #USA #New_Haven #BHV-7000 #Major_Depressive_Disorder #Biohaven_Ltd.

CAPLYTA® Receives FDA Approval: A New Hope for Major Depressive Disorder Treatment The FDA's approval of CAPLYTA® offers new hope for adults with major depressive disorder, enabling potential remission and enhanced treatment options.

CAPLYTA® Receives FDA Approval: A New Hope for Major Depressive Disorder Treatment #USA #Johnson_&_Johnson #Major_Depressive_Disorder #CAPLYTA #Titusville,_NJ

Johnson & Johnson Showcases Innovative Treatments for Major Depressive Disorder at ECNP 2025 Johnson & Johnson will present groundbreaking research on major depressive disorder and treatment-resistant depression at the 2025 ECNP Congress, showcasing 17 abstracts.

Johnson & Johnson Showcases Innovative Treatments for Major Depressive Disorder at ECNP 2025 #USA #Johnson_&_Johnson #Major_Depressive_Disorder #treatment-resistant_depression #Titusville,_NJ

NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials Cumulus Neuroscience presents groundbreaking findings demonstrating the NeuLogiq® Platform's ability to identify key electrophysiological signals in patients with Major Depressive Disorder, enhancing clinical trials.

NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials #United_States #Scottsdale,_Arizona #Cumulus_Neuroscience #Major_Depressive_Disorder #NeuLogiq_Platform

Gilgamesh Pharmaceuticals Reveals Groundbreaking Phase 2a Results for Innovative Antidepressant GM-2505 Gilgamesh Pharmaceuticals has announced promising Phase 2a results for GM-2505, a novel antidepressant for Major Depressive Disorder. The drug shows rapid and sustained effects.

Gilgamesh Pharmaceuticals Reveals Groundbreaking Phase 2a Results for Innovative Antidepressant GM-2505 #United_States #New_York #Major_Depressive_Disorder #Gilgamesh_Pharmaceuticals #GM-2505

Primary Care Doctors Essential in Addressing Mental Health Issues Among Youths A new study highlights how primary care physicians are pivotal in diagnosing and addressing Major Depressive Disorder among youth in America, focusing on significant trends and necessary solutions.

Primary Care Doctors Essential in Addressing Mental Health Issues Among Youths #USA #mental_health #Premera_Blue_Cross #Mountlake_Terrace #Major_Depressive_Disorder

Groundbreaking Study Links Brain Blood Flow to Major Depression Biomarker, Thanks to Amen Clinics A recent study in JAMA Psychiatry highlights brain blood flow as a crucial biomarker for Major Depressive Disorder, showcasing Amen Clinics' vital contribution to mental health diagnostics.

Groundbreaking Study Links Brain Blood Flow to Major Depression Biomarker, Thanks to Amen Clinics #United_States #Costa_Mesa #Amen_Clinics #Major_Depressive_Disorder #Brain_Imaging